Summit Therapeutics plc (SMMT)
After hours:
| Previous close | 3.8600 |
| Open | 3.8800 |
| Bid | 3.8800 x 400 |
| Ask | 3.9200 x 400 |
| Day's range | 3.8550 - 4.0600 |
| 52-week range | 1.4400 - 5.2200 |
| Volume | |
| Avg. volume | 2,140,083 |
| Market cap | 2.724B |
| Beta (5Y monthly) | -1.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9900 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.50 |
Business WireSummit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
MIAMI, April 24, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens.
Business WireSummit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
MIAMI, April 11, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately.
Business WireSummit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
MIAMI, April 10, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at the Stifel 2024 Targeted Oncology Forum, which will be held virtually April 16-17, 2024. Dr. Maky Zanganeh, Chief Executive Officer and President, Robert W. Duggan, Chairman and Chief Executive Officer, Manmeet Soni, Chief Operating Officer & Chief Financial Officer, Dave Gancarz, Chief Business & Strategy Officer, and Dr. Allen S. Yang, Chi
